Several BET inhibitors are in development and have been shown to have activity across various subtypes of AML in mouse models including MLL-fusion leukemias [48], as well as leukemias bearing mutations in NPM1, Flt3-ITD and DNMT3A [47, 50, 51]. This evidence concerns the gene NPM1 and leukemia.